Ashvattha Therapeutics Announces Poster Presentation of Preclinical Data on Hydroxyl Dendrimer-Based Therapeutics at the 2022 Neurofibromatosis (NF) Conference

Error message

Notice: Undefined property: stdClass::$ds_changed in eval() (line 16 of /var/www/7/modules/php/php.module(80) : eval()'d code).
Notice: Undefined property: stdClass::$ss_search_api_url in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
Notice: Undefined property: stdClass::$tm_title in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).

REDWOOD CITY, Calif., June 07, 2022 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (Ashvattha), a clinical stage company developing novel hydroxyl dendrimer therapeutics, today announced a poster presentation of preclinical data demonstrating its hydroxyl dendrimer-based therapeutics reduce toxicity in targeted delivery to plexiform neurofibroma, a slow growing tumor associated with neurofibromatosis type 1 (NF1), at the 2022 Neurofibromatosis (NF) Conference hosted by the Childrens Tumor Foundation and taking place at Loews Philadelphia Hotel in Philadelphia, PA, June 18 21, 2022.

Metadata

Provider:

GlobeNewswire, Inc.

Retrieved on:

Tuesday, June 7, 2022

Information

Geotags:

REDWOOD CITY, CALIFORNIA, US, PA, PHILADELPHIA

Organisation:

ASHVATTHA THERAPEUTICS

Summary

Key Points:

REDWOOD CITY, Calif., June 07, 2022 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (Ashvattha), a clinical stage company developing novel hydroxyl dendrimer therapeutics, today announced a poster presentation of preclinical data demonstrating its hydroxyl dendrimer-based therapeutics reduce toxicity in targeted delivery to plexiform neurofibroma, a slow growing tumor associated with neurofibromatosis type 1 (NF1), at the 2022 Neurofibromatosis (NF) Conference hosted by the Childrens Tumor Foundation and taking place at Loews Philadelphia Hotel in Philadelphia, PA, June 18 21, 2022.
Poster presentation details can be found below:
Ashvattha Therapeutics is a clinical-stage biotech company developing novel hydroxyl dendrimer therapeutics (HDTs) targeting unmet medical needs in neurology, ophthalmology, inflammatory diseases, and neuro-oncology.
The therapies are based on hydroxyl dendrimers (HDs), a targeted platform technology exclusively licensed from our founders, Kannan Rangaramanujam and Sujatha Kannan at Johns Hopkins University.
HDs chemically conjugated to disease modifying drugs create novel proprietary HD therapeutics (HDTs) selectively targeting reactive inflammatory cells in disease tissue with localized sustained effects.

REDWOOD CITY, Calif., June 07, 2022 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical stage company developing novel hydroxyl dendrimer therapeutics, today announced a poster presentation of preclinical data demonstrating its hydroxyl dendrimer-based therapeutics reduce toxicity in targeted delivery to plexiform neurofibroma, a slow growing tumor associated with neurofibromatosis type 1 (NF1), at the 2022 Neurofibromatosis (NF) Conference hosted by the Children’s Tumor Foundation and taking place at Loews Philadelphia Hotel in Philadelphia, PA, June 18 – 21, 2022.

Poster presentation details can be found below:

Title: Hydroxyl Dendrimer Therapeutics Reduce Toxicity in Targeted Delivery to Plexiform Neurofibroma
Presenter: Emma C. Mazurek
Date: Sunday, June 19, 2022
Time: 5:40 – 7:40 p.m. ET
Location: Loews Philadelphia Hotel, Millennium Hall, Second Floor

About Ashvattha Therapeutics
Ashvattha Therapeutics is a clinical-stage biotech company developing novel hydroxyl dendrimer therapeutics (HDTs) targeting unmet medical needs in neurology, ophthalmology, inflammatory diseases, and neuro-oncology. The therapies are based on hydroxyl dendrimers (HDs), a targeted platform technology exclusively licensed from our founders, Kannan Rangaramanujam and Sujatha Kannan at Johns Hopkins University. HDs chemically conjugated to disease modifying drugs create novel proprietary HD therapeutics (HDTs) selectively targeting reactive inflammatory cells in disease tissue with localized sustained effects. Ashvattha has initiated multiple programs with HDTs focused on neurology, ocular neovascular disease including neovascular age-related macular degeneration (AMD) and diabetic macular edema (DME), and hyperinflammation in diseases such as COVID-19. For more information, visit: www.avttx.com.

Media Contact
Jordyn Temperato
LifeSci Communications
[email protected]